Special Offers & Promotions



Latest News



View Channel

New Products



View Channel

Separation Science



View Channel

Microscopy & Image Analysis



View Channel

Laboratory Automation & IT Solutions



View Channel


Merck Expands Life Science Production Capacities in the United States

publication date: Dec 14, 2020
author/source: Merck


Combined expansion of Danvers, Massachusetts, and Jaffrey, New Hampshire, USA facilities to create nearly 700 new positions

Merck, a leading science and technology company, has announced the broadening of its manufacturing footprint with a combined €40 million investment at its production facilities in Danvers, Massachusetts, and Jaffrey, New Hampshire, USA. These sites supply critical products to customers developing lifesaving therapies, including Covid-19 vaccines, as well as provide products and services for biopharmaceutical manufacturing. These expansions will significantly increase capacity and output at these facilities by the end of 2021 and 2022, respectively, and create nearly 700 new manufacturing positions.

“The global coronavirus pandemic has significantly increased demand for our single-use and virus filtration technologies, which we are supplying to more than 50 different companies working on Covid-19 vaccine candidates,” said Chris Ross, interim head, Life Science, at Merck. “These investments will strengthen our global manufacturing footprint, allowing us to meet this unprecedented demand and help get lifesaving vaccines and therapies to more patients, faster.”

This expansion will add 6,000 square meters of space to the Danvers single-use assembly operation, adding to the existing 11,000-square-meter facility. The expansion will add the capacity needed to support the manufacturing of products across several portfolios, including Merck’s Mobius® single-use consumables. The total investment in Danvers is about € 21 million and will add approximately 400 jobs throughout 2021.

The Jaffrey expansion plans include adding 2,300 square meters to the existing 24,000-square-meter facility. The additional capacity includes new production lines and equipment to support the manufacturing of filtration devices and membrane products, specifically Durapore® filters, Express® filters and the Viresolve® product line s. These products are used to ensure the sterility of many lifesaving therapies and to remove viral contamination for a variety of therapies. The total investment in Jaffrey is about  € 18.5 million. This expansion is expected to bring nearly 275 roles by 2022, once the expansion is completed.

These expansions join the Life Science investments announced in 2020 to further enhance capabilities and capacity in Buchs, Switzerland; Carlsbad, California, USA; Madison, Wisconsin, USA; and Darmstadt, Germany, broadening the company’s global manufacturing footprint. 


more news from Merck


If you have not logged into the website then please enter your details below.


Subscribe to any of our newsletters for the latest on new laboratory products, industry news, case studies and much more!

Newsletters from Lab Bulletin


Request your free copies HERE




Popular this Month

Top 10 most popular articles this month



Today's Picks



Looking for a Supplier?

Search by company or by product


Company Name:






Please note Lab Bulletin does not sell, supply any of the products featured on this website. If you have an enquiry, please use the contact form below the article or company profile and we will send your request to the supplier so that they can contact you directly.

Lab Bulletin is published by newleaf marketing communications ltd.


Exhibitions & Events

Media Partner